Unicycive Therapeutics (UNCY) Times Interest Earned (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Times Interest Earned came in at -$0.71 in Q1 2026, up 99.11% YoY from -$0.36 in Q1 2025, and down 104.22% on a QoQ basis from $16.84 in Q4 2025.
Unicycive Therapeutics (UNCY) Times Interest Earned (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Times Interest Earned data on file, last reported at -$0.71 in Q1 2026.
- Quarterly Times Interest Earned rose 99.11% year-over-year to -$0.71 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.53 (up 98.53% YoY) and the FY2025 annual result came in at -$1.15, up 29.58% from the prior year.
- Times Interest Earned retreated to -$0.71 in Q1 2026, from $16.84 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $237.46 in Q4 2024 to a low of -$1775.0 in Q4 2022.
- A 5-year average of -$123.73 and a median of -$7.18 in 2024 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 171.47% in 2024, down 501649.42% in 2024.
- Tracing UNCY's Times Interest Earned over 5 years: stood at -$1775.0 in 2022, then jumped by 81.28% to -$332.26 in 2023, then soared by 171.47% to $237.46 in 2024, then sank by 92.91% to $16.84 in 2025, then sank by 104.22% to -$0.71 in 2026.
- The last three Times Interest Earned figures came in at -$0.71 (Q1 2026), $16.84 (Q4 2025), and -$0.98 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.28 |
| Mar 31, 2026 | -0.71 |
| Dec 31, 2025 | 16.84 |
| Sep 30, 2025 | -0.98 |
| Jun 30, 2025 | -1.29 |
| Mar 31, 2025 | -79.89 |
| Dec 31, 2024 | 237.46 |
| Sep 30, 2024 | -7.18 |
| Jun 30, 2024 | -10.68 |
| Mar 31, 2024 | -92.04 |
| Dec 31, 2023 | -332.26 |
| Sep 30, 2023 | -0.17 |
| Jun 30, 2023 | -0.04 |
| Mar 31, 2023 | -0.02 |
| Dec 31, 2022 | -1,775.00 |
| Sep 30, 2022 | -28.63 |
| Jun 30, 2022 | -15.67 |
| Mar 31, 2022 | -13.15 |
| Dec 31, 2021 | 14.19 |
| Sep 30, 2021 | -85.73 |